经支气管动脉灌注化疗联合栓塞术治疗中晚期肺癌的临床疗效

摘要

Objective To investigate the clinical efficacy of bronchial arterial perfusion chemotherapy embolization (BACE) in treating mid-stage and advanced lung cancer (LC). Methods One hundred cases of mid-stage and advanced LC treat-ed in our hospital from July 2011 to June 2013 were included in this study and divided into the BACE group and systemic venous chemotherapy(SVC) group according to the random numbers generated by computer,50 cases in each group. The patients in the BACE group were given the BACE treatment at first,and then SVC was performed,while the SCV group was only performed the SCV treatment. The clinical efficacies,levels of T lymphocyte factors including CD3+,CD4+,CD8+and CD4+/CD8+,the one-year and three-year survival rates and adverse reactions were compared between the two groups. Results After treatment,the levels of CD3+,CD4+and CD4+/CD8+in the two groups were increased,while CD8+level was decreased,the difference com-pared with before treatment was statistically significant(P<0.05);the levels of CD3+,CD4+and CD4+/CD8+in the BACE group were higher than those in the SVC group,while the CD8+level was lower than that in the SVC group,the difference was statisti-cally significant(P<0.05). The total remission rate in the BACE group was 92.00%(46/50),which was higher than 76.00%(38/50) in the SVC group,the difference was statistically significant(P<0.05). The one-year survival rate and three-year survival rate in the BACE group were 92.00%(46/50) and 74.00%(37/50),which were higher than 76.00%(38/50) and 54.00%(27/50),the difference was statistically significant(P<0.05). The occurrence rate of adverse reactions had no statistical difference between the BACE group and the SVC group. Conclusions BACE in treating mid-stage and advanced LC can effectively correct the cell-mediated immunity imbalance state of the body,the clinical efficacy is remarkable,the one-year or three-year survival rate is high,and the adverse effects rate during treatment has no significant difference from SVC treatment,so BACE is worthy of applica-tion in clinic.%目的：探讨经支气管动脉灌注化疗联合栓塞术（bronchi artery perfusion chemotherapy embolism，BACE）治疗中晚期肺癌（lung cancer，LC）的临床疗效。方法将2011年7月至2013年6月在该院接受治疗的中晚期LC患者100例纳入本研究，依据电脑生成的随机数字分为BACE组与全身静脉化疗（SVC）组，各50例。BACE 组患者均先行BACE治疗，再行SVC；SCV组仅行SCV治疗。比较两组临床疗效，治疗前后CD3+、CD4+、CD8+、CD4+/CD8+等T淋巴细胞因子水平，1、3年生存率及不良反应发生情况。结果治疗后，两组CD3+、CD4+水平及CD4+/CD8+均增加，CD8+水平降低，与治疗前比较，差异均有统计学意义（P＜0.05）；BACE组CD3+、CD4+水平及CD4+/CD8+高于SVC组，CD8+水平低于SVC组，差异均有统计学意义（P＜0.05）。BACE组总缓解率[92.00%（46/50）]高于SVC组[76.00%（38/50）]，差异有统计学意义（P＜0.05）。BACE 组1、3年生存率[92.00%（46/50）、74.00%（37/50）]均高于SVC组[76.00%（38/50）、54.00%（27/50）]，差异均有统计学意义（P＜0.05）。治疗期间BACE组不良反应发生率与SVC组比较，差异无统计学意义（P＞0.05）。结论 BACE治疗中晚期LC可有效纠正机体细胞免疫失衡状态，疗效显著，1、3年生存率高，且治疗期间不良反应发生率与SVC无显著差异，值得在临床推广应用。